Hostname: page-component-5c6d5d7d68-wbk2r Total loading time: 0 Render date: 2024-08-20T23:29:35.396Z Has data issue: false hasContentIssue false
  • English
  • Français

The opiate system in Gilles de la Tourette syndrome: diverse effects of naltrexone treatment

Published online by Cambridge University Press:  16 April 2020

N Müller ,
A Putz  and
A Straube
N Müller
Affiliation:
Psychiatrische Klinik, Klinikum lnnenstadt, Nuβbaumstr 7, D-80336 , Munich
A Putz
Affiliation:
Psychiatrische Klinik, Klinikum lnnenstadt, Nuβbaumstr 7, D-80336 , Munich
A Straube
Affiliation:
Neurologische Klinik, Klinikum Groβhardern, Marchioninistr 15, D-81366 , Munich, Germany
Get access

Summary

The main symptoms of Gilles de la Tourette syndrome (GTS) are motor and vocal tics, but there are also several psychiatric disturbances such as obsessive compulsive symptoms (OCD) and mutilations. The etiology and pathophysiology of this basal ganglia disorder are unknown. Though many patients benefit from therapy with dopamine antagonists, the effect is often insufficient. Therapeutic efficacy of the opiate antagonist naltrexone has been described in recent years. Ten patients (three f, seven m) with GTS were invesitgated in a seven-week, open dose-response trial, using naltrexone in doses ranging from 12.5 mg to 200 mg/day. The severity of the GTS symptoms were rated with the Yale Global Tic Severity Scale (YGTSS) and the Tourette Syndrome Global Scale (TSGS); OCD was estimated by the Maudsley Obsessive Compulsive Inventory (MOCI). The course of tics and psychopathology was assessed by three self-report scales, and two scales rated by clinicians (Clinical Global Impression, CGI; Brief Psychiatric Rating Scale, BPRS). Only two patients showed improvement of the GTS. In four patients, no effect was observed, whereas the other four patients exhibited deterioration. One patient finished the complete trial, three patients dropped out because of lack of improvement, and four because of deterioration of the symptoms. Considering the mean values, no improvement of GTS could therefore be observed, and because of the unpredictable effect, the study was stopped after ten patients. Nevertheless, the effects were quite controversial. The opiate system seems to be affected only in some of the GTS patients in a clinically relevant manner, and opiate antogonists can either improve or provoke GTS symptoms. Pathophysiologically different subgroups of GTS may contribute to the controversal results.

Keywords

Tourette's syndromeopiate systemdopamine systemnaltrexone
Type
Original article
Information
European Psychiatry , Volume 9 , Issue 1 , 1994 , pp. 39 - 44
Copyright
Copyright © Elsevier, Paris 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Balthasar, K. Über das anatomische Substrat der generalisierten Tic-Krankheit (maladie des tics, Gilles de la Tourette): Entwicklunghemmung des Corpus striatum. Arch f Psychiatrie und Zeitschr f d ges Neurologie 1957:195:531–49Google Scholar
Barrett, RPFeinstein, CHole, WT. Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. Am J Ment Ret 1989:93:644–51Google ScholarPubMed
Chesselet, MFCheranny, AReisine, TD. Morphine and delta-opioid agonists locally stimulate in vivo dopamine release in rat caudate nucleus. Nature 1981:291:320–lCrossRefGoogle Scholar
Cohen, DJShaywitz, BAYoung, CGCarbonari, CMNathanson, JALiebermann, DBowers, MB JrMaas, JW. Central biogenic amine metabolism in children with syndrome of chronic multiple tics of Gilles de la Tourette: norepinephrine, serotonin, and dopamine. J Am Acad Child Psychiatr 1979:18:320–41CrossRefGoogle ScholarPubMed
Comings, DEComings, BG. A controlled family history study of Tourette's Syndrome. III: Affective and other disorders. J Clin Psychiatry 1991a:51:288–90Google Scholar
Comings, DEComings, BG. Clinical and genetic relationship between autismpervasive developmental disorder and Tourette syndrome: a study of 19 cases. Am J Med Genetics 199lb;39:180–91CrossRefGoogle Scholar
Donnai, D. Gene location in Tourette's Syndrome. Lancet i: 1987:637Google Scholar
Erenberg, GLederman, RJ. Naltrexone and Tourette's syndrome. Neurology 1992:574Google ScholarPubMed
Gerfen, CRMcGinty, JFYoung, WSIII. Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 1991:11:1016–31CrossRefGoogle Scholar
Gillman, MASandyk, R. Tourette syndrome: effects of analgesic concentrations of nitrous oxide and naloxone. Br Med J 1984:288:114Google Scholar
Gillman, MASandyk, R. Tourette syndrome and the opioid system. Psychiatry Res 1985;15:161–2CrossRefGoogle ScholarPubMed
Gillman, MASandyk, R. The endogenous opioid system in Giiles de la Tourette syndrome. Med Hypotheses 1986;19:371–8CrossRefGoogle ScholarPubMed
Graybiel, AM. Neurotransmitters and neuromodulators in the basal ganglin. Trends Neurosci 1990:13:244–54CrossRefGoogle Scholar
Goetz, CG. Tics: Giiles de la Tourette syndrome.In: Vinken, PJBruyn, GWKlawans, HI eds. Handbook of clinical neurology. Amsterdam:Elsevier Science Publishers, 1986:5:49:627–39Google Scholar
Haber, SNKowell, NWVonsattel, JPBird, EDRichardson, EP. Gilles de la Tourette's syndrome: a postmortem neuropathological and histochemical study. J Neurol Sci 1986;75:225–41CrossRefGoogle Scholar
Harcherik, DFLeckman, JFDetlor, JCohen, DJ. A new instrument for clinical studies of Tourette's syndrome. J Am Acad Child Psychiatry 1984;23:153–60CrossRefGoogle ScholarPubMed
Herman, BHHammock, MKArthur-Smith, AEgan, JChatoor, IWerner, AZelnik, N. Naltrexone decreases self-injurious behavior. Ann Neurol 1987;22:550–2CrossRefGoogle ScholarPubMed
Hodgson, RJRachman, S. Obsessional-compulsive complaints. Behav REs & Therapy 1977;15:389–95CrossRefGoogle ScholarPubMed
Höllt, V. Regulation of opioid gene expression.In: Herz, A. ed. Handbook of Experimental Pharmacology 104/1. Heidelberg:Springer, 1993:307–46Google Scholar
Knabe, RBovier, P. Pharmacological treatment of extreme self-injurious behavior in autism. Eur Psychiatry 1992;7:297–8Google Scholar
Kurlan, RMajumdar, LDeeley, CMudholkar, GPlumb, SComo, PG. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann Neurol 1991;30:19–23CrossRefGoogle ScholarPubMed
Lakke, JPWFWilmink, JT. A case of Gilles de la Tourette's syndrome with midbrain involvement. J Neurol Neurosurg Psychiatry 1985;48:1293–96CrossRefGoogle ScholarPubMed
Leboyer, MBouvard, MPLaunnay, JMTabuteau, FWaller, DDugas, MKerdelhue, DLensing, PPanksepp, J. Brief report: a double blind study of naltrexone in infantile autism. J Autism Dev Disor 1992:22:309–19CrossRefGoogle ScholarPubMed
Leckman, JFRiddle, MAHardin, MTOrt, SISwartz, KLStevenson, JCohen, DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989:28:566–73CrossRefGoogle ScholarPubMed
Lohr, JBWisniewski, AA. Tourette's syndrome and related conditions.In: Movement Disorders. A Neuropsychiatric Approach. J Wiley & Sons Publ. 1987:191–200Google Scholar
Lichter, DMajumdar, LKurlan, R. Opiate withdrawal unmasks Tourette syndrome. Clin Neuropharmacol 1988:6:559–64CrossRefGoogle Scholar
Mesulam, MMPetersen, RC. Treatment of Gilles de la Tourette's syndrome: Eight-year, practise-based experience in a predominantly adeft population. Neurology 1987:37:1828–33CrossRefGoogle Scholar
Meuidijk, RColon, EJ. Methadone treatment of Tourette's disorder. Am J Psychiatry 1992:149:39–140Google Scholar
Müller, N. Exacerbation of tics following antidepressant therapy in a case of Gilles-de-la-Tourette-syndrome. Pharmacopsychiatry 1992:25:243–4Google Scholar
Müller, NStraube, A. Gilles-de-la-Tourette-Syndrom und Zwangsneurose: Der Beitrag organischer Befunde zur Differentialdiagnose. Psycho 1989;15:420–1Google Scholar
Müller, NDurst, PStraube, AMüller-Spahn, F. Symptomes obsessionnels et compulsifs majeurs lors de syndromes de Gilles-de-la-Tourette: une contribution au diagnostic différentiel de syndromes obsessionnels et compulsifs. J Psychiatrie Biol Ther 1989:33:37–41Google Scholar
Müller, NGünther, WBscheid, IHaag, CKlages, UPutz, ABaghai, TStraube, A. Quantitative EEG-Analyse bei Gilles-de-la-Tourette-Syndrome. Erste Ergebnisse einer 32-Kanal-EEG-Mapping-Studie. Nervenheilkunde (108, Wanderversammlung Südwestdeutscher Neurologen und Psychiater) 1992a;48–51Google Scholar
Müller, NStraube, AKlages, UPutz, A. The influence of the opiate system on the pathogenesis of the Gilles de la Tourette syndrome. Movement 1992b;Dis 7 (suppl 1)51Google Scholar
Müller, NVoderholzer, UKurtz, GStraube, A. Tourette's syndrome associated with restless legs syndrome and akathisia in a family. Acta Neurol Scand 1994a (in press)Google Scholar
Müller, NPutz, AKlages, UHofschuster, EStraube, AAckenheil, M. Blunted growth hormone response to clinidine in Gilles de la Tourette syndrome. Psychoneuroendocrinology 1994b (in press)CrossRefGoogle Scholar
National Institute of Mental Health.In: Guy, WBonato, RR. eds. ECDEU Assessment Manual for psychopharmacology. Maryland:Rev Ed Rockville. 1970:217–22Google Scholar
Nee, LECaine, EDPolinsky, RJEldridge, REbert, MH. Gilles de la Tourette syndrome: clinical and family study of 50 cases. Ann Neurol 1980:7:41–9CrossRefGoogle ScholarPubMed
Overall, JEGorham, DR. Brief psychiatric rating scale.In: ECDEU Assessment Manual for Psychopharmacology (Guy, W ed). Maryland: Rev Ed Rockville, 1976:157–69Google Scholar
Ostrowski, NLHatfield, CBCaggiula, AR. The effects of low doses of morphine on the activity of dopamine containing ceils and on behavior. Life Sci 1982:31:2347–50CrossRefGoogle Scholar
Pakstis, AJHeutink, PPauls, DLKurian, Rvan de Wetering, BJMLeckman, JFSandkuyl, LAKidd, JRBreedveld, GLCastiglione, CMWeber, JSparkes, RSCohen, DJKidd, KKOostra, BA. Progress in the search for genetic linkage with Tourette syndrome: a exclusion map covering more than 50% of the autosomal genome. Am J Hum Genet 1991:48:281–94Google ScholarPubMed
Peterson, BRiddle, MACohen, DJKatz, MDSmith, BAHardin, MTLeckman, JF. Reduced basal ganglia volumes in Tourette's syndrome using three-dimensional reconstruction techniques from magnetic resonance images. Neurology 1993;43:941–9CrossRefGoogle ScholarPubMed
Pulst, SMWalshe, TMRomero, JA. Carbon monoxide poisoning with features of Gilles de la Tourette's syndrome. Arch Neurol 1983;40:443–4CrossRefGoogle ScholarPubMed
Robertson, MM. The Gilles de la Tourette Syndrome: the Current Status. Br J Psychiatry 1989:154:147–69CrossRefGoogle ScholarPubMed
Sandyk, R. Tourette syndrome and the opioid system. Psychiatry Res 1985:15:161–162Google Scholar
Sandyk, R. Naloxone withdrawal exacerbates Tourette syndrome. J Clin Pharmacol 1986a ,6:58–9Google Scholar
Sandyk, R. Tourette syndrome: successful treatment with clonidine and oxycodone. J Neurol 1986b;233:178–9CrossRefGoogle Scholar
Sandyk, RBamford, CR. Gonadotropin reponse to naloxone challenge in Tourette's syndrome. Neurology 1987;37(suppl):277Google Scholar
Sandyk, RBamford, CRIacono, RPCrinnian, C. Abnormal growth hormone response to naloxone challenge in Tourette's syndrome. Int J Neurosci 1987a:3:191–2CrossRefGoogle Scholar
Sandyk, RBamford, CRWendt, J. Naltrexone suppresses self-multilatory behavior in Tourette's syndrome. Neurology 1987b:37(supp):277Google Scholar
Smith, SJMLees, AJ. Abnormalities of the blink reflex in Gilles de la Tourette syndrome. J Neurol Neurosurg Psychiatry 1989;52:895–8CrossRefGoogle ScholarPubMed
Shapiro, AKShapiro, EWayne, HClarkin, J. Organic factors in Gilles de la Tourette's syndrome. Br J Psychiatry 1973;122:659–64CrossRefGoogle ScholarPubMed
Shapiro, AKShapiro, ESYoung, JGFeinberg, TE. Gilles de la Tourette Syndrome. 2nd edn New York: Raven Press, 1988Google Scholar
Singer, HSHahn, IHMoran, TH. Abnormal dopamine uptake sites from patients with Tourette's syndrome. Ann Neurol 1991;30:558–62CrossRefGoogle ScholarPubMed
Singer, HSTune, LEButler, UZaczek, RCoyle, JT. Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette syndrome.In: Friedhoff, AJChase, TN eds. Gilles de la Tourette Syndrome. New York: Raven Press, 1982:177–83Google Scholar
Singer, HSReiss, ALBrown, JEAylward, EHShih, BChee, EHarris, ELReader, MJChase, GABryan, RNDenckla, MB. Volumetric MRI changes in basal ganglia of children with Tourette's syndrome. Neurology 1993:43:350CrossRefGoogle ScholarPubMed
Zerssen, DvKoeller, DMRey, ER. Die Befindlichkeitsskala (B-S) – ein einfaches Instrument zur Objecktivierung von Befindlichkeitsstörungen, insbesondere im Rahmenn von Längsschnitt-Untersuchungen. Arzneim Forsch 1970:20:915–8Google Scholar
Submit a response

Comments

No Comments have been published for this article.